Previous studies, including observations from our group, have indeed demonstrated that treatment with TGFα or EGF increased in MSCs the production of several factors which might promote tumor growth and/or angiogenesis, such as VEGF, IL6, angiopoietin-2 (ANG-2), granulocyte-colony-stimulating factor (G-CSF), hepatocyte growth factor (HGF) and heparin-binding EGF (HB-EGF) [15, 18, 19]. The gene discussed is CSF3; the disease is neoplasm.